中国药业
中國藥業
중국약업
China Pharmaceuticals
2015年
21期
85-87
,共3页
紫杉醇脂质体%顺铂注射液%三维适形放射治疗%晚期食管癌
紫杉醇脂質體%順鉑註射液%三維適形放射治療%晚期食管癌
자삼순지질체%순박주사액%삼유괄형방사치료%만기식관암
paclitaxel liposome%cisplatin injection%three-dimensional conformal radiotherapy%advanced esophageal cancer
目的 探讨紫杉醇脂质体、顺铂注射液联合三维适形放射治疗(简称放疗)对晚期食管癌患者生存质量的影响.方法 选择医院收治的晚期食管癌患者48例,随机分为对照组和观察组,各24例.所有患者均采用三维适形放疗,并于放疗第1天同步联合不同化学治疗(简称化疗)方案,观察组患者采用紫杉醇联合顺铂化疗方案,对照组患者采用5-氟尿嘧啶联合顺铂化疗方案,4周为1个疗程,共治疗2个疗程.结果 治疗后观察组近期疗效为91. 67%,显著高于对照组的75. 00%( P<0. 05);两组患者生存质量较治疗前均显著改善,且观察组改善程度更明显( P<0. 05);观察组患者吞咽困难、疼痛、梗阻、咳嗽等症状改善程度均显著优于对照组( P<0. 05);观察组患者3年生存率明显高于对照组( P<0. 05);观察组总不良反应发生率显著低于对照组( P<0. 05).结论 紫杉醇脂质体、顺铂注射液联合三维适形放疗治疗晚期食管癌,近期疗效好,能显著改善患者的生存质量及临床症状,提高3年生存率,且不良反应较少,值得推广.
目的 探討紫杉醇脂質體、順鉑註射液聯閤三維適形放射治療(簡稱放療)對晚期食管癌患者生存質量的影響.方法 選擇醫院收治的晚期食管癌患者48例,隨機分為對照組和觀察組,各24例.所有患者均採用三維適形放療,併于放療第1天同步聯閤不同化學治療(簡稱化療)方案,觀察組患者採用紫杉醇聯閤順鉑化療方案,對照組患者採用5-氟尿嘧啶聯閤順鉑化療方案,4週為1箇療程,共治療2箇療程.結果 治療後觀察組近期療效為91. 67%,顯著高于對照組的75. 00%( P<0. 05);兩組患者生存質量較治療前均顯著改善,且觀察組改善程度更明顯( P<0. 05);觀察組患者吞嚥睏難、疼痛、梗阻、咳嗽等癥狀改善程度均顯著優于對照組( P<0. 05);觀察組患者3年生存率明顯高于對照組( P<0. 05);觀察組總不良反應髮生率顯著低于對照組( P<0. 05).結論 紫杉醇脂質體、順鉑註射液聯閤三維適形放療治療晚期食管癌,近期療效好,能顯著改善患者的生存質量及臨床癥狀,提高3年生存率,且不良反應較少,值得推廣.
목적 탐토자삼순지질체、순박주사액연합삼유괄형방사치료(간칭방료)대만기식관암환자생존질량적영향.방법 선택의원수치적만기식관암환자48례,수궤분위대조조화관찰조,각24례.소유환자균채용삼유괄형방료,병우방료제1천동보연합불동화학치료(간칭화료)방안,관찰조환자채용자삼순연합순박화료방안,대조조환자채용5-불뇨밀정연합순박화료방안,4주위1개료정,공치료2개료정.결과 치료후관찰조근기료효위91. 67%,현저고우대조조적75. 00%( P<0. 05);량조환자생존질량교치료전균현저개선,차관찰조개선정도경명현( P<0. 05);관찰조환자탄인곤난、동통、경조、해수등증상개선정도균현저우우대조조( P<0. 05);관찰조환자3년생존솔명현고우대조조( P<0. 05);관찰조총불량반응발생솔현저저우대조조( P<0. 05).결론 자삼순지질체、순박주사액연합삼유괄형방료치료만기식관암,근기료효호,능현저개선환자적생존질량급림상증상,제고3년생존솔,차불량반응교소,치득추엄.
Objective To discuss the influence of paclitaxel liposome combined with cisplatin in the three-dimensional conformal radio-therapy on the living quality of patients with advanced esophageal cancer. Methods 48 patients with advanced esophageal cancer from January 2011 to January 2012 were randomly divided into control group and observation group, 24 cases in each group. All patients were treated with three-dimensional conformal radiotherapy, and were combined with different chemotherapy regimens on the first day of radiotherapy, with docetaxel plus cisplatin chemotherapy ( observation group ) and five-fluorouracil plus cisplatin chemotherapy ( control group ) respectively. 4 weeks was 1 course of treatment, and with a total of 2 courses of treatment. Results After treatment, the recent curative effect of observation group was 91. 67%, which was significantly higher than 75. 00% in the control group ( P < 0. 05 ); the quality of life of the two groups of patients were significantly improved compared with before treatment, and the improvement in the ob-servation group was better than that of control group ( P < 0. 05 );symptoms such as dysphagia, pain and obstruction in the observation group were significantly better than the control group ( P < 0. 05 );at the end of follow-up, the 3 years survival rate of the observation group was higher than the control group ( P < 0. 05 );total incidence rate of adverse reactions in observation group was significantly low-er than the control group ( P < 0. 05 ) . Conclusion Paclitaxel liposome combined with cisplatin in the three-dimensional conformal ra-diotherapy in treating advanced esophageal cancer has a good short-term effect, can significantly improve the quality of life and clinical symptoms, improve the 3 years survival rate and has relatively fewer adverse reactions, which is worthy of clinical promotion.
